TMDA (Tanzania)

TMDA (Tanzania Medicines and Medical Devices Authority) is the United Republic of Tanzania's national regulatory authority responsible for the regulation of medicines + medical devices + IVDs + cosmetics + tobacco products. TMDA was originally established in 2003 as the Tanzania Food and Drugs Authority (TFDA) under the Tanzania Food, Drugs and Cosmetics Act Cap 219, succeeding the Pharmacy Board of Tanzania + the Food Quality Control Board. The Finance Act No. 8 of 2019 renamed + reconstituted TFDA as TMDA + transferred food regulation to the Tanzania Bureau of Standards (TBS) — narrowing TMDA's mandate to medicines + medical devices + diagnostics + cosmetics + tobacco. TMDA headquarters relocated to Dodoma in 2017 alongside Tanzania's capital-relocation programme + the agency maintains a substantial Dar es Salaam office + zonal offices across Tanzania.

TMDA's organisational structure includes:

• Director General — chief executive appointed by the Minister of Health + accountable to the Ministerial Advisory Board; serves a fixed term renewable.
• Ministerial Advisory Board — chaired by a Ministerial appointee + including the Director General + representatives of the Pharmaceutical Council of Tanzania + Medical Association of Tanzania + Ministry of Health + Ministry of Livestock + civil society.
• Directorate of Medicines + Cosmetics — drug + biological + biosimilar + vaccine + herbal-medicine + cosmetic + tobacco-product registration.
• Directorate of Medical Devices + Diagnostics — medical-device + IVD registration + classification + post-market materiovigilance.
• Directorate of Pharmacovigilance + Clinical Trials — National Pharmacovigilance Centre + clinical-trial oversight + ADR reporting + signal detection.
• Directorate of Laboratory Services — operates the WHO-prequalified Tanzania National Quality Control Laboratory (NCQAL) in Dar es Salaam.
• Directorate of Inspectorate + Enforcement — GMP / GDP / GCP inspection of Tanzanian + foreign facilities + ports-of-entry + counterfeit-medicine enforcement.
• Directorate of Port Health Services — border-post + airport + seaport inspection + importation control.
• Directorate of Business Support + ICT — finance, ICT, HR + administration.
• Directorate of Communication + Risk Communication — consumer education + risk communication + media relations.

TMDA's consolidated product-regulator model (covering medicines + devices + diagnostics + cosmetics + tobacco under a single agency) is shared with peer EAC NRAs (Kenya PPB + Uganda NDA + Rwanda FDA) reflecting common-law colonial-era legislative inheritance + East African regulatory tradition. Unlike Kenya PPB, TMDA does NOT regulate pharmacy practice or pharmacy premises licensing — those functions sit with the Pharmacy Council of Tanzania (PCT). Unlike pre-2019 TFDA, TMDA does NOT regulate food — that function transferred to the Tanzania Bureau of Standards (TBS) under the Finance Act 2019.

TMDA is distinct from + complementary to: the Pharmacy Council of Tanzania (PCT, which regulates pharmacy practice + pharmacists + pharmacy premises); the Medical Council of Tanganyika (MCT, which regulates medical + dental practice); the Tanzania Bureau of Standards (TBS, which regulates food + non-health-related industrial standards); the National Institute for Medical Research (NIMR, which conducts health research + collaborates on clinical trials + clinical-trial ethics review); the Government Chemist Laboratory Authority (GCLA, which handles forensic + non-pharmaceutical chemistry); + the Tanzania Veterinary Council (TVC, which regulates veterinary practice — though veterinary medicines are regulated by TMDA jointly with the Ministry of Livestock).

Legal foundations are the Tanzania Food, Drugs and Cosmetics Act Cap 219 of 2003 (as substantially amended by the Finance Act No. 8 of 2019), the TMDA Guidelines on Submission of Documentation for Registration of Human Medicinal Products, the TMDA Good Manufacturing Practice Guidelines, the TMDA Medical Devices and IVDs Guidelines + a substantial body of TMDA technical guidelines.

TMDA achieved WHO Maturity Level 3 (ML3) for medicines in December 2018 — the first sub-Saharan African NRA to achieve ML3 for medicines under the WHO Global Benchmarking Tool framework. TMDA is pursuing WHO Maturity Level 3 for vaccines + WHO Listed Authority (WLA) status as near-term milestones. TMDA has applied for PIC/S Membership + is an active participant in WHO PQ CRP, EAC-MRH, ZAZIBONA, AMRH + ICDRA.

Tanzanian pharmaceutical regulation operates under a layered framework of primary legislation + TMDA guidelines:

• Tanzania Food, Drugs and Cosmetics Act Cap 219 of 2003 (as amended by the Finance Act No. 8 of 2019) — primary legislation establishing TMDA + its functions, powers + governance; provides for Board appointment + Director General + the 2019 narrowing-of-mandate transferring food to TBS.
• Tanzania Industrial Hemp Regulations 2020 — controlled-substance scheduling for industrial hemp + cannabis-derived products.
• Tobacco Products (Regulation) Act 2003 — tobacco-product regulation administered by TMDA.
• TMDA Guidelines on Submission of Documentation for Registration of Human Medicinal Products — current registration framework for medicines + biologicals + biosimilars + vaccines.
• TMDA Guidelines for Registration of Herbal + Complementary Medicinal Products — herbal medicines + nutraceuticals framework.
• TMDA Good Manufacturing Practice Guidelines — current Tanzanian GMP guidelines substantively aligned with WHO TRS 986 Annex 2 + ICH Q7 + EU GMP; mandatory for Tanzanian + foreign manufacturers exporting to Tanzania.
• TMDA Good Clinical Practice Guidelines — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in Tanzania.
• TMDA Good Distribution Practice Guidelines — substantively aligned with WHO + EU GDP.
• TMDA Pharmacovigilance Guidelines + Tanzania National Pharmacovigilance System Strategic Plan — substantively aligned with WHO + EU GVP Modules; Tanzania operates the Yellow Form + ADR reporting + mobile-pharmacovigilance pilots.
• TMDA Medical Devices and IVDs Guidelines — risk-based Class A-D framework substantively aligned with GHTF/IMDRF + EU MDR + ISO 13485 with Tanzanian-specific overlay.
• TMDA Cosmetics Guidelines — registration + labelling + safety substantiation for cosmetics + cosmetovigilance reporting.
• TMDA Variations Guidelines — Type IA / IB / II variations procedure substantively similar to WHO + EU + EAC-MRH variations framework.
• TMDA Promotion and Advertisement of Medicines Guidelines — pre-approval of medicines + medical-device advertising + promotional materials.
• TMDA Tobacco Products Regulations — registration, labelling, advertising restrictions + plain-packaging considerations for tobacco products.

Tanzania's National Quality Control Laboratory (NCQAL) is operated by TMDA + located in Dar es Salaam. NCQAL is WHO-prequalified for pharmaceutical quality control + serves both TMDA + WHO Prequalification + Global Fund + Gavi + USAID procurement programmes.

• WHO-Prequalified Laboratory (PQ-Lab) — NCQAL achieved WHO Prequalification of Quality Control Laboratories status + maintains it through periodic WHO inspections; one of only a handful of African PQ-Labs (NQCL Kenya + NCQAL Tanzania + LANSPEX Cameroon + LNCQM Burkina Faso + a few others).
• TMDA regulatory laboratory — NCQAL conducts pre-registration quality testing + post-market surveillance testing + lot-release testing on behalf of TMDA; results are direct TMDA regulatory evidence.
• WHO PQ contract laboratory — NCQAL conducts independent quality testing for WHO PQ programmes including HIV / TB / malaria / reproductive-health / maternal-child-health medicines.
• Global Fund + Gavi + USAID contract laboratory — NCQAL conducts independent quality testing for Global Fund + Gavi + USAID procurement programmes serving Tanzania + the East African Community + SADC + broader Africa.
• ISO/IEC 17025-accredited — NCQAL is ISO/IEC 17025-accredited for pharmaceutical chemical + microbiological + biological testing.
• Regional reference role — NCQAL provides quality-control testing services for EAC + SADC Partner States that lack in-country WHO-prequalified laboratory capacity + supports EAC-MRH + ZAZIBONA regional pharmacovigilance + counterfeit-medicine forensics.
• Counterfeit-medicine forensics — NCQAL conducts forensic chemical analysis on suspect counterfeit medicines + supports TMDA Inspectorate + Tanzania Police Force enforcement.
• Capacity-building role — NCQAL hosts training programmes for African pharmaceutical analysts + contributes to WHO + AUDA-NEPAD regulatory-strengthening initiatives.

TMDA medical-device + IVD regulation operates under the TMDA Medical Devices and IVDs Guidelines with a Class A-D risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint a Tanzanian Authorised Representative (TAR).

• Risk-based Classification (Class A / B / C / D + IVD Class A-D) — substantively aligned with GHTF/IMDRF + EU MDR/IVDR with Tanzanian-specific overlay.
• Registration Certificate — issued by TMDA Directorate of Medical Devices + Diagnostics based on technical-file review + Tanzanian Authorised Representative designation + English/Kiswahili labelling.
• Tanzanian Authorised Representative (TAR) — Tanzanian-resident legal entity required for foreign manufacturers; bears post-market materiovigilance responsibility + Tanzanian regulatory interface.
• ISO 13485:2016 — recognised by TMDA as QMS evidence framework; Tanzanian-specific overlay required including Tanzanian quality records + TAR QMS interface.
• Reliance pathways — TMDA accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• MDSAP — Tanzania is not currently an MDSAP Participating Regulator + does not accept MDSAP audit reports as direct QMS evidence; ISO 13485 + Tanzanian-specific overlay required.
• Post-market Materiovigilance — TMDA operates medical-device adverse-event reporting through the Yellow Form + mobile-pharmacovigilance pilots; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under TMDA Cosmetics Guidelines require registration + Tanzanian-specific labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting.
• Tanzanian UDI — TMDA has not implemented full UDI equivalent to FDA UDI or EU EUDAMED UDI; Tanzanian-specific labelling + product-identification requirements apply.
• Importation Permit — TMDA Importation Permit required in addition to registration for foreign-manufactured devices entering Tanzania.

TMDA operates the Tanzania National Pharmacovigilance Centre (NPC) under the Directorate of Pharmacovigilance + Clinical Trials. Tanzania has been a long-standing WHO Programme for International Drug Monitoring (PIDM) member + has contributed substantial ADR data to VigiBase via Uppsala Monitoring Centre.

• Yellow Form — paper-based ADR reporting form available in English + Kiswahili + distributed through healthcare facilities + pharmacies.
• Mobile pharmacovigilance pilots — TMDA has piloted mobile-app-based pharmacovigilance reporting tools following the Kenya PPB Med Safety App + WHO PIDM mHealth pharmacovigilance models.
• National Pharmacovigilance Centre (NPC) — TMDA Directorate of Pharmacovigilance + Clinical Trials operates the NPC + conducts ADR signal detection + risk-benefit analysis + risk communication.
• WHO PIDM Member — Tanzania is a long-standing WHO Programme for International Drug Monitoring member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• E2B(R3) ICSR — TMDA accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); TMDA-specific submission timeline + Tanzanian-population focus.
• Active surveillance — TMDA operates targeted active-surveillance programmes including for HIV antiretrovirals + malaria + tuberculosis medicines + COVID-19 vaccines + sentinel-site hospital surveillance through Muhimbili National Hospital + KCMC + Bugando + regional referral hospitals.
• Cosmetovigilance — TMDA operates cosmetovigilance reporting including for skin-lightening + mercury + hydroquinone cosmetic safety issues.

• WHO Maturity Level 3 (ML3) for Medicines (December 2018) — first sub-Saharan African NRA to achieve ML3 under the WHO Global Benchmarking Tool framework + a landmark for African regulatory maturity.
• WHO ML3 vaccines + WLA pursuit — TMDA is pursuing WHO Maturity Level 3 for vaccines + WHO Listed Authority (WLA) status as near-term milestones.
• WHO PQ Collaborative Registration Procedure (CRP) — active WHO PQ CRP Recipient with substantial use of CRP for vaccines + HIV + malaria + tuberculosis + reproductive-health medicines.
• WHO PQ Laboratory — NCQAL is one of a handful of African WHO-prequalified pharmaceutical quality-control laboratories.
• WHO PIDM (Programme for International Drug Monitoring) — long-standing Tanzania membership; substantial VigiBase ADR contribution.
• AUDA-NEPAD AMRH — leading participant in African Medicines Regulatory Harmonisation programme; co-leads EAC-MRH work-stream alongside PPB + NDA + Rwanda FDA + participates in SADC ZAZIBONA work-stream alongside SAHPRA.
• EAC-MRH (East African Community Medicines Regulatory Harmonisation) — TMDA is a leading EAC NRA + co-leads EAC-MRH Joint Assessment Procedure across 6 EAC Partner States (Kenya + Tanzania + Uganda + Rwanda + Burundi + South Sudan; + DR Congo since 2022).
• ZAZIBONA Collaborative Medicines Registration Initiative — Tanzania uniquely participates in BOTH EAC-MRH AND ZAZIBONA (SADC), reflecting Tanzania's dual EAC + SADC membership; TMDA + SAHPRA are frequent co-Reference Authorities under ZAZIBONA.
• African Medicines Agency (AMA) — AU continental medicines agency under AMA Treaty (entered into force November 2021); Tanzania is a leading AMA Member State + Tanzania hosts senior AMA Secretariat positions.
• PIC/S Application — TMDA has applied for PIC/S Membership; TMDA GMP Guidelines + inspectorate practices substantively aligned with PIC/S GMP Guide + Annexes.
• ICDRA Member — active International Conference of Drug Regulatory Authorities participant; hosts ICDRA-related Africa-Region preparatory meetings.
• ICH Observer — TMDA is an ICH Observer; ICH guidelines extensively referenced in Tanzanian regulatory practice.
• Bilateral MoUs — TMDA holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + ANVISA + NMPA + MFDS + NAFDAC + Ghana FDA + SAHPRA + Egyptian EDA + PPB + NDA + Rwanda FDA + Ugandan + Burundian + South Sudanese counterparts.
• Gavi / Global Fund / Gates Foundation / USAID cooperation — TMDA works closely with Gavi (vaccine procurement), Global Fund (HIV/TB/malaria procurement), Gates Foundation (regulatory strengthening) + USAID (PEPFAR + maternal-child health programmes); NCQAL serves as procurement QC lab.
• IMDRF Affiliate — TMDA is an IMDRF Affiliate Member + draws on IMDRF guidance for medical-device regulation.

• Tanzanian Authorised Representative or local Sponsor not properly designated — application rejected at TMDA intake or post-approval compliance failure.
• Tanzanian-specific labelling deficiencies — English + Kiswahili labelling + Tanzanian-Shilling pricing-reference + Tanzanian PIL + storage-condition Tanzanian-climate appropriateness.
• GMP Guidelines gaps — applicants assuming EU GMP / PIC/S GMP compliance is sufficient without addressing Tanzania-specific TMDA GMP Guidelines + TMDA-specific clarifications.
• Tanzanian climate-zone stability data missing — Tanzanian Climate Zone IVa/IVb (hot + dry to hot + humid; Dar es Salaam coastal zone IVb) stability data required for medicines + biologicals; many EU-only + US-only stability packages insufficient.
• WHO PQ CRP eligibility not leveraged — WHO-PQ-approved products eligible for accelerated CRP review at TMDA; missed opportunity for substantial review time + cost reduction.
• EAC-MRH + ZAZIBONA dual-membership not leveraged — Tanzania uniquely participates in BOTH EAC-MRH AND ZAZIBONA; sponsors targeting multiple African markets can leverage TMDA as a bridging Reference Authority across East + Southern Africa.
• Food-regulator confusion — pre-2019 TFDA regulated food; post-2019 TMDA does NOT regulate food (transferred to TBS under Finance Act 2019); applicants sometimes file food applications to TMDA in error.
• Pharmacy practice scope misunderstood — unlike Kenya PPB, TMDA does NOT regulate pharmacy practice or premises licensing (handled by Pharmacy Council of Tanzania); avoid filing practice applications to TMDA.
• Tobacco-product scope underestimated — TMDA regulates tobacco products under the Tobacco Products (Regulation) Act 2003; tobacco sponsors must engage TMDA + comply with plain-packaging + advertising-restriction frameworks.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to WHO but with Tanzania-specific timelines + fee structure.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Importation Permit not obtained — TMDA Importation Permit required in addition to registration for foreign-manufactured medicines + devices entering Tanzania.
• Port-of-entry inspection gaps — TMDA Port Health Services inspection at Dar es Salaam + Tanga + Mtwara seaports + JNIA + KIA airports + land borders; importer logistics planning must account for inspection clearance time.
• Pharmacovigilance reporting gaps — TMDA Pharmacovigilance requirements substantively similar to WHO GVP + EU GVP but with Tanzanian-specific format requirements + Tanzanian-population pharmacovigilance focus + Kiswahili-language ICSR option.
• Clinical trial COSTECH gap — Tanzanian clinical trials require TMDA CTA + NIMR-ERC + COSTECH (Tanzania Commission for Science and Technology) authorisation; sponsors sometimes overlook the COSTECH step.

V5 Ultimate provides the operational infrastructure Tanzanian + foreign-supplier sites need for Tanzania Food, Drugs and Cosmetics Act Cap 219 + TMDA GMP Guidelines + TMDA Drug Registration + TMDA Medical Devices Guidelines + EAC-MRH + ZAZIBONA + WHO PQ CRP + NCQAL readiness.

• TMDA GMP Guidelines control framework — WHO TRS 986 Annex 2 + ICH Q7 + EU GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Tanzania-specific clarifications + Tanzanian climate-zone IVa/IVb stability monitoring.
• TMDA drug-registration packaging — Tanzanian CTD-aligned dossier structure with Tanzania Module 1 specifics + Module 3 stability + Tanzanian PIL + English/Kiswahili labelling + Tanzanian Authorised Representative declarations.
• WHO PQ CRP workflow — CRP Recipient packaging with WHO PQ Assessment Report + TMDA-specific overlay + reduced dossier + accelerated 90-day review path.
• EAC-MRH workflow — EAC-MRH joint assessment + reliance pathway packaging for multi-country East African registration including Kenya + Tanzania + Uganda + Rwanda + Burundi + South Sudan + DRC.
• ZAZIBONA workflow — Tanzania-specific dual-membership packaging leveraging TMDA's participation in BOTH EAC-MRH AND ZAZIBONA to bridge East + Southern African registration.
• AMRH + AMA workflow — AU AMA + AUDA-NEPAD AMRH reliance pathway packaging for continental coverage.
• Tanzanian Authorised Representative workflow — foreign-manufacturer TAR designation + role-management + Tanzania-specific post-market surveillance + TMDA interface.
• Tanzanian clinical-trial workflow — TMDA Good Clinical Practice + NIMR-ERC + COSTECH + Tanzania-population pharmacovigilance + TMDA CTA submission + Tanzanian SUSAR reporting.
• TMDA Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Kiswahili-language ICSR option + TMDA NPC + VigiBase upload.
• Cosmetovigilance + tobacco workflow — TMDA Cosmetics Guidelines + Tobacco Products Regulations packaging + Tanzanian cosmetic + tobacco adverse-event reporting + Tanzanian-specific labelling + advertising controls.
• Medical-device + cosmetic + nutraceutical workflow — TMDA Medical Devices Guidelines + Cosmetics Guidelines + Nutraceutical Guidelines dossier packaging + Class A-D + IVD classification + ISO 13485 + Tanzanian Authorised Representative + post-market materiovigilance.
• TMDA Variations workflow — Type IA / IB / II classification + TMDA procedure + Tanzanian packaging.
• Renewal workflow — 5-year renewal window tracking + TMDA procedure packaging.
• EAC + SADC + AU regional bridging — for companies operating across East + Southern Africa + Africa, V5 surfaces TMDA + PPB + NDA + Rwanda FDA + Burundi DPML + South Sudan DFDA + DRC ACOREP + SAHPRA + Zambia ZAMRA + Zimbabwe MCAZ + Botswana DRA + Namibia NMRC + Malawi PMRA + Mozambique INAMED + Eswatini MRA + NAFDAC + Ghana FDA + Egyptian EDA harmonised dossier-element reuse alongside national-specific extensions.